Neuronal Adenosine A2A Receptors Are Critical Mediators of Neurodegeneration Triggered by Convulsions

eNeuro. 2018 Dec 26;5(6):ENEURO.0385-18.2018. doi: 10.1523/ENEURO.0385-18.2018. eCollection 2018 Nov-Dec.

Abstract

Neurodegeneration is a process transversal to neuropsychiatric diseases and the understanding of its mechanisms should allow devising strategies to prevent this irreversible step in brain diseases. Neurodegeneration caused by seizures is a critical step in the aggravation of temporal lobe epilepsy, but its mechanisms remain undetermined. Convulsions trigger an elevation of extracellular adenosine and upregulate adenosine A2A receptors (A2AR), which have been associated with the control of neurodegenerative diseases. Using the rat and mouse kainate model of temporal lobe epilepsy, we now tested whether A2AR control convulsions-induced hippocampal neurodegeneration. The pharmacological or genetic blockade of A2AR did not affect kainate-induced convulsions but dampened the subsequent neurotoxicity. This neurotoxicity began with a rapid A2AR upregulation within glutamatergic synapses (within 2 h), through local translation of synaptic A2AR mRNA. This bolstered A2AR-mediated facilitation of glutamate release and of long-term potentiation (LTP) in CA1 synapses (4 h), triggered a subsequent synaptotoxicity, heralded by decreased synaptic plasticity and loss of synaptic markers coupled to calpain activation (12 h), that predated overt neuronal loss (24 h). All modifications were prevented by the deletion of A2AR selectively in forebrain neurons. This shows that synaptic A2AR critically control synaptic excitotoxicity, which underlies the development of convulsions-induced neurodegeneration.

Keywords: adenosine; convulsions; neuroprotection; synapse; synaptotoxicity; synatic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine A2 Receptor Antagonists / therapeutic use
  • Amygdala / physiology
  • Animals
  • Cells, Cultured
  • Convulsants / toxicity*
  • Epilepsy / complications
  • Epilepsy / drug therapy
  • Epilepsy / etiology
  • Hippocampus / drug effects
  • Hippocampus / physiology
  • Kainic Acid / toxicity*
  • Kindling, Neurologic / drug effects
  • Kindling, Neurologic / physiology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nerve Degeneration / etiology*
  • Nerve Degeneration / metabolism*
  • Nerve Degeneration / prevention & control
  • Neurons / drug effects
  • Neurons / metabolism*
  • Protein Binding / drug effects
  • Pyrimidines / therapeutic use
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A2A / genetics
  • Receptor, Adenosine A2A / metabolism*
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / genetics
  • Triazoles / therapeutic use

Substances

  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Adenosine A2 Receptor Antagonists
  • Convulsants
  • Pyrimidines
  • Receptor, Adenosine A2A
  • Triazoles
  • Kainic Acid